Key Points
- Septerna COO Elizabeth Bhatt sold 4,000 shares at an average price of $37.41, generating $149,640 and reducing her direct stake by 2.24% to 174,209 shares.
- Septerna recently reported stronger-than-expected quarterly results, with an adjusted loss of $0.29 per share versus the $0.43 consensus estimate and revenue of $26.75 million.
- Wall Street remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $52.44, although the stock trades at about $36.38 and one analyst maintains a sell rating.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) COO Elizabeth Bhatt sold 4,000 shares of the business's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total value of $149,640.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company's stock, valued at $6,517,158.69. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Elizabeth Bhatt also recently made the following trade(s):
- On Tuesday, August 11th, Elizabeth Bhatt sold 25,000 shares of Septerna stock. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00.
Septerna Stock Up 0.1%
NASDAQ:SEPN opened at $36.38 on Tuesday. Septerna, Inc. has a twelve month low of $17.55 and a twelve month high of $51.10. The stock's 50-day simple moving average is $39.25 and its 200 day simple moving average is $33.66. The firm has a market capitalization of $1.70 billion, a PE ratio of -67.37 and a beta of 2.29.
Septerna (NASDAQ:SEPN - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.14. The firm had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. On average, analysts anticipate that Septerna, Inc. will post -1.41 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Engineers Gate Manager LP lifted its holdings in Septerna by 5.0% in the second quarter. Engineers Gate Manager LP now owns 17,350 shares of the company's stock valued at $581,000 after buying an additional 822 shares during the period. Strs Ohio boosted its position in Septerna by 17.8% during the first quarter. Strs Ohio now owns 17,200 shares of the company's stock valued at $413,000 after acquiring an additional 2,600 shares during the last quarter. Squarepoint Ops LLC grew its holdings in Septerna by 17.3% during the 2nd quarter. Squarepoint Ops LLC now owns 21,219 shares of the company's stock worth $711,000 after acquiring an additional 3,136 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna during the 4th quarter worth about $88,000. Finally, Bank of New York Mellon Corp grew its holdings in Septerna by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company's stock worth $1,411,000 after acquiring an additional 3,377 shares during the period.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on SEPN. Guggenheim upped their price target on shares of Septerna from $45.00 to $51.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on Septerna from $38.00 to $48.00 and gave the company an "overweight" rating in a research note on Wednesday, August 19th. JonesTrading lifted their price target on shares of Septerna from $43.00 to $62.00 and gave the stock a "buy" rating in a report on Thursday, August 13th. Truist Financial increased their price target on Septerna from $35.00 to $43.00 and gave the company a "buy" rating in a research note on Wednesday, July 1st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Septerna in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $52.44.
Get Our Latest Stock Analysis on Septerna
Septerna Company Profile
(
Get Free Report)
Septerna, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.
The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
